SecBot SecBot
PRESS-RELEASE ·Filed Aug 14, 2026

NMRA

Neumora Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming data readouts for NMRA-511 (AD agitation, Q4 2026) and NMRA-898 (schizophrenia, H2 2026) as key catalysts. Cash runway into Q3 2027 provides no near-term financing urgency, but any clinical setbacks could pressure the stock given the poor historical performance.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

NMRA drug pipeline →

NMRA-511

◆ Mixed Named in this press release
Impact
Phase
Phase 1b/2a
Time to market
At least 3-5 years away, assuming successful Phase 2 and Phase 3 trials. The drug is still in early clinical development (Phase 1b/2a).
Next catalyst
None dated

What to watchWatch for NMRA-511 MAD expansion cohort data in Q4 2026, positive results could drive a significant rally given the stock's ~$1.04 price and 380% implied analyst upside, but negative data would pressure shares. The company has multiple shots on goal (navacaprant, NMRA-898, NMRA-215), so NMRA-511 is not a single-point-of-failure.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.60
T+0 close · Aug 14, 2026 · via day close
Latest settled
−69.63%
T+60 · $0.4859
Vs SPY
−66.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $1.60entry
  2. T+1 · 3mo ago −5.00%α −4.53% · $1.52
  3. T+5 · 3mo ago +1.88%α +3.24% · $1.63
  4. T+20 · 2mo ago −37.54%α −35.55% · $0.9994
  5. T+60 · 8d ago −69.63%α −66.58% · $0.4859

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neumora Therapeutics reported Q2 2026 EPS of -$0.23, exactly in line with consensus, with no revenue. Cash and equivalents of $116.8M are expected to fund operations into Q3 2027. Pipeline milestones remain on track for H2 2026, including data readouts for NMRA-511 and NMRA-898, and an IND submission for NMRA-215. Leadership changes include a new CEO and CMO.

Key Financial Metrics

EPS
−$0.23
est −$0.23 · 0.0%
Revenue
$0.00
est $0.00 · 0.0%
Rating
in line

Key Facts

  • Q2 2026 EPS of -$0.23 in line with consensus of -$0.23
  • Cash and cash equivalents of $116.8M as of June 30, 2026; cash runway into Q3 2027
  • Net loss improved to $43.1M from $52.7M in Q2 2025
  • R&D expense decreased to $29.3M from $38.7M YoY
  • NMRA-215 IND submission planned for Q4 2026 with Phase 1 start by end of 2026
  • NMRA-511 MAD expansion cohort data in AD agitation expected Q4 2026
  • NMRA-898 Phase 1 data in schizophrenia expected H2 2026
  • Joshua Pinto, Ph.D., appointed CEO; Doron Sagman, M.D., appointed CMO

Financial Impact

No material financial impact; net loss improved 18% YoY but remains significant relative to cash position.

net losscash positionR&D expenseG&A expense

Risk Factors

  • Clinical trial failures or delays for pipeline candidates
  • Dilution risk if additional capital is needed beyond current cash runway
  • Leadership transition execution risk

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
80% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345232

Track record

14 reports on NMRA

Performance horizon

3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.33% at T+60 after the Aug 20, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.3760 Now $0.3700 −1.60% settles Nov 24
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry $0.4206 Now $0.3700 −12.03% settles Nov 23
  3. Oct 30, 202617d ago 8-K Bearish 7/10 Entry $0.4957 to $0.4859 Now $0.3700 +25.36% ▲ +1.98% +2.06% vs SPY
  4. Sep 22, 20267w ago Institutional Cluster Neutral 3/10 Entry $0.7785 to $0.6776 Now $0.3700 −52.47% ▼ −12.96% −11.77% vs SPY
  5. Aug 20, 202612w ago 144 Bearish 5/10 Entry $1.63 to $1.39 Now $0.3700 +77.30% ▲ +14.72% +15.20% vs SPY
  6. Aug 17, 202613w ago 144 Bearish 5/10 Entry $1.64 to $1.50 Now $0.3700 +77.44% ▲ +8.54% +8.34% vs SPY
  7. Aug 14, 202613w ago 8-K Neutral 4/10 No price data
  8. Aug 14, 202613w ago Press Release Neutral 4/10 Viewing Entry $1.60 to $1.63 Now $0.3700 −76.87% ▲ +1.88% +3.24% vs SPY
  9. Jul 27, 202616w ago 8-K Bullish 5/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
  10. Jul 27, 202616w ago Press Release Bullish 7/10 Entry $1.66 to $1.61 Now $0.3700 −77.71% ▼ −3.01% −4.09% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026